GET THE APP

Phenotype related diagnosis and culprit drug(s) detection after drug eruptions. Validation of a new rapid preformed IL-6 release assay from patients T-lymphocytes by in vivo tests
Journal of Clinical & Experimental Dermatology Research

Journal of Clinical & Experimental Dermatology Research
Open Access

ISSN: 2155-9554

+1-504-608-2390

Phenotype related diagnosis and culprit drug(s) detection after drug eruptions. Validation of a new rapid preformed IL-6 release assay from patients T-lymphocytes by in vivo tests


5th International Conference on Clinical & Experimental Dermatology

July 13-15, 2015 New Orleans, USA

Balo Banga J M

ScientificTracks Abstracts-Workshop: J Clin Exp Dermatol Res

Abstract :

Recently an International Consensus (ICON) on Drug Allergy has been published. This document includes skin and provocation tests in the diagnostic workup after drug eruptions but does not recommend in vitro assays because of lacking standardization. Humoral tests available on the market have low sensitivity; T-cell based cellular tests depend on cell cultures which last 3-5 days and has many requirements. Their results are often difficult to interpret for clinicians especially in relation of diverse phenotypic expression of drug induced skin injuries. Our aim was to overcome those problems by introducing a rapid reproducible assay based on preformed IL-6 release by the patientā??s mononuclear cells. Earlier, detection of the culprit drug induced rapid changes was done by morphometry on T-cell nuclei after short exposure to simple media and using 4-10 sequential molarity based drug dilutions.The present methods included ELISA-based measurement of rapid specific release of IL-6 from isolated mononuclear cells upon 20 minutes incubation with 0.15-0.5 Ī¼M (final) solutions of pure drugs (mol. mass 76-4000 Da) with either PHA-P or ConA as positive controls. ConA increased IL-6 release in concentration and time dependent manner. This indicated a preformed cellular pool for this cytokine. The test results have reflected both severity and surface extensions only with culprit drugs (n=43) of various Clinical & Experimental Dermatology and revealed a 85.4% sensitivity against in vivo challenges.

Biography :

Balo-Banga (J. Matyas) has graduated from Semmelweis Medical University, Budapest. After residency and specialization in dermatology-venereology he was Assistant Professor in the Dept. of Experimental Oncology at Indiana University Purdue University, Indianapolis. After returning from the US he defended his PhD Thesis in Budapest and became specialist in laboratory medicine and in allergy-immunology. Up to 1989 he participated in basic and clinical research with the Austrian Centre Seibersdorf. In the 1990-s he was elected as Secretary General of the Hungarian Dermatologic Society. After 28 years at the University Dermatology Department he became Head of the Dermatology in the Military Hospital. He wrote or edited 20 books & book chapters and has ~40 papers cited in international medical databases.

Top